# Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)

> **NCT00287157** · PHASE1 · COMPLETED · sponsor: **Teva GTC** · enrollment: 5 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** Sublingual Tizanidine HCl

## Key facts

- **NCT ID:** NCT00287157
- **Lead sponsor:** Teva GTC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2009-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287157, "Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00287157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*